This work was expanded by Venteicher et al. with a larger cohort of 16 patients across IDH-Mut astrocytomas (IDH-A, characterized by secondary TP53 and ATRX mutations) and IDH-Mut oligodendrogliomas (IDH-O, with codeletion of chromosome arms 1p and 19q).20 This study discovered multiple salient findings that were shared across IDH-A and IDH-O gliomas. This evidence concerns the gene ATRX and central nervous system cancer.